Lynn Morris

List of Publications by Year
in descending order

148 papers	14,475 citations	22153 59 h-index	19749 117 g-index
149 all docs	149 docs citations	149 times ranked	10405 citing authors

#	Article	IF	Citations
1	Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines. Nature Communications, 2022, 13, 903.	12.8	7
2	Infection of Chinese Rhesus Monkeys with a Subtype C SHIV Resulted in Attenuated In Vivo Viral Replication Despite Successful Animal-to-Animal Serial Passages. Viruses, 2021, 13, 397.	3.3	1
3	Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms. Viruses, 2021, 13, 1296.	3.3	3
4	mRNA vaccines offer hope for HIV. Nature Medicine, 2021, 27, 2082-2084.	30.7	9
5	Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope. Journal of Virology, 2020, 94, .	3.4	15
6	The complex challenges of HIV vaccine development require renewed and expanded global commitment. Lancet, The, 2020, 395, 384-388.	13.7	44
7	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. PLoS ONE, 2020, 15, e0234937.	2.5	3
8	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: AÂrandomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Medicine, 2020, 17, e1003038.	8.4	27
9	Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. Cell Reports, 2020, 31, 107488.	6.4	53
10	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. , 2020, 15, e0234937.		0
11	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. , 2020, 15, e0234937.		0
12	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. , 2020, 15, e0234937.		0
13	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. , 2020, 15, e0234937.		0
14	Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage. PLoS Pathogens, 2019, 15, e1008005.	4.7	6
15	Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000â€“2016: A Pooled Sequence Analysis. EClinicalMedicine, 2019, 9, 26-34.	7.1	51
16	High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. Cell, 2019, 179, 1636-1646.e15.	28.9	219
17	Engineered HIV antibody passes muster. Lancet HIV,the, 2019, 6, e641-e642.	4.7	1
18	Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies. Journal of Virology, 2019, 93, .	3.4	13

#	Article	IF	Citations
19	V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. Cell Reports, 2018, 25, 3123-3135.e6.	6.4	23
20	Measuring the ability of HIV-specific antibodies to mediate trogocytosis. Journal of Immunological Methods, 2018, 463, 71-83.	1.4	32
21	HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes. Journal of Virology, 2018, 92, .	3.4	47
22	Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection. Cell Host and Microbe, 2018, 23, 845-854.e6.	11.0	100
23	Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses. Aids, 2017, 31, 2199-2209.	2.2	13
24	Prospects for passive immunity to prevent HIV infection. PLoS Medicine, 2017, 14, e1002436.	8.4	29
25	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathogens, 2017, 13, e1006074.	4.7	33
26	Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection. Science Translational Medicine, 2016, 8, 358ra125.	12.4	121
27	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. EBioMedicine, 2016, 12, 196-207.	6.1	34
28	Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy. Antimicrobial Agents and Chemotherapy, 2016, 60, 2248-2256.	3.2	17
29	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. Cell Reports, 2016, 14, 43-54.	6.4	45
30	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. Journal of Virology, 2016, 90, 76-91.	3.4	205
31	HIV broadly neutralizing antibody targets. Current Opinion in HIV and AIDS, 2015, 10, 135-143.	3.8	110
32	South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on Î±4Î²7 for replication. Retrovirology, 2015, 12, 54.	2.0	19
33	Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage. PLoS ONE, 2015, 10, e0131906.	2.5	26
34	HIV Disease Progression in Seroconvertors from the CAPRISA 004 Tenofovir Gel Pre-exposure Prophylaxis Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 55-61.	2.1	10
35	Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis. Lancet Infectious Diseases, The, 2015, 15, 803-809.	9.1	47
36	Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients. AIDS Research and Human Retroviruses, 2015, 31, 776-782.	1.1	14

#	Article	IF	Citations
37	Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Trends in Microbiology, 2015, 23, 204-211.	7.7	77
38	Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLoS Medicine, 2015, 12, e1001810.	8.4	188
39	Impact of Drug Resistance-Associated Amino Acid Changes in HIV-1 Subtype C on Susceptibility to Newer Nonnucleoside Reverse Transcriptase Inhibitors. Antimicrobial Agents and Chemotherapy, 2015, 59, 960-971.	3.2	48
40	Population-Based Surveillance of HIV Drug Resistance Emerging on Treatment and Associated Factors at Sentinel Antiretroviral Therapy Sites in Namibia. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 463-471.	2.1	14
41	Ability To Develop Broadly Neutralizing HIV-1 Antibodies Is Not Restricted by the Germline Ig Gene Repertoire. Journal of Immunology, 2015, 194, 4371-4378.	0.8	85
42	The use of dried blood spot specimens for HIV-1 drug resistance genotyping in young children initiating antiretroviral therapy. Journal of Virological Methods, 2015, 223, 30-32.	2.1	8
43	Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nature Medicine, 2015, 21, 1332-1336.	30.7	215
44	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host and Microbe, 2015, 18, 354-362.	11.0	66
45	Differences in HIV Type 1 Neutralization Breadth in 2 Geographically Distinct Cohorts in Africa. Journal of Infectious Diseases, 2015, 211, 1461-1466.	4.0	7
46	Viral Suppression Following Switch to Second-line Antiretroviral Therapy: Associations With Nucleoside Reverse Transcriptase Inhibitor Resistance and Subtherapeutic Drug Concentrations Prior to Switch. Journal of Infectious Diseases, 2014, 209, 711-720.	4.0	47
47	Viral Escape Pathways from Broadly Neutralising Antibodies Targeting the HIV Envelope Cleavage Site Enhance MPER Mediated Neutralisation. AIDS Research and Human Retroviruses, 2014, 30, A20-A21.	1.1	1
48	The Sequence of the Î±4Î²7-binding Motif on Gp120 of Transmitted/Founder Viruses Contributes to the Dependence on the Integrin for HIV Infection. AIDS Research and Human Retroviruses, 2014, 30, A56-A56.	1.1	1
49	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature, 2014, 509, 55-62.	27.8	681
50	Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies. Cell Host and Microbe, 2014, 16, 304-313.	11.0	137
51	Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. Journal of Virological Methods, 2014, 207, 182-187.	2.1	5
52	HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria. Cell Host and Microbe, 2014, 16, 215-226.	11.0	105
53	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature, 2014, 514, 455-461.	27.8	702
54	Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. Infection, Genetics and Evolution, 2013, 18, 125-131.	2.3	58

#	Article	IF	Citations
55	Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes. PLoS Pathogens, 2013, 9, e1003738.	4.7	190
56	The Antibody Response against HIV-1. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a007039-a007039.	6.2	152
57	Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. Virology, 2012, 433, 410-420.	2.4	12
58	Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. Journal of Experimental Medicine, 2012, 209, 1469-1479.	8.5	156
59	International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II. PLoS ONE, 2012, 7, e36438.	2.5	63
60	The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4 ⁺ T Cell Decline and High Viral Load during Acute Infection. Journal of Virology, 2011, 85, 4828-4840.	3.4	441
61	Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop. Journal of Virology, 2011, 85, 3128-3141.	3.4	151
62	Randomized Trial of Time-Limited Interruptions of Protease Inhibitor-Based Antiretroviral Therapy (ART) vs. Continuous Therapy for HIV-1 Infection. PLoS ONE, 2011, 6, e21450.	2.5	8
63	Extreme Genetic Divergence Is Required for Coreceptor Switching in HIV-1 Subtype C. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 9-15.	2.1	38
64	HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. Aids, 2011, 25, 1461-1469.	2.2	39
65	Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study. BMC Public Health, 2011, 11, 88.	2.9	69
66	Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual. Journal of Virology, 2011, 85, 7719-7729.	3.4	54
67	Detection of Low-Level K65R Variants in Nucleoside Reverse Transcriptase Inhibitorâ€“Naive Chronic and Acute HIV-1 Subtype C Infections. Journal of Infectious Diseases, 2011, 203, 798-802.	4.0	26
68	Adherence to Drug-Refill Is a Useful Early Warning Indicator of Virologic and Immunologic Failure among HIV Patients on First-Line ART in South Africa. PLoS ONE, 2011, 6, e17518.	2.5	84
69	Drug Resistance Patterns and Virus Re-Suppression among HIV-1 Subtype C Infected Patients Receiving Non-Nucleoside Reverse Transcriptase Inhibitors in South Africa. Journal of AIDS & Clinical Research, 2011, 02, .	0.5	30
70	Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design. Journal of Virological Methods, 2010, 164, 122-126.	2.1	16
71	Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology, 2010, 402, 187-196.	2.4	95
72	Reuse of Nevirapine in Exposed HIV-Infected Children After Protease Inhibitorâ€“Based Viral Suppression. JAMA - Journal of the American Medical Association, 2010, 304, 1082.	7.4	75

#	Article	IF	Citations
73	Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. Aids, 2010, 24, 1679-1687.	2.2	100
74	Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science, 2010, 329, 1168-1174.	12.6	2,239
75	International Network for Comparison of HIV Neutralization Assays: The NeutNet Report. PLoS ONE, 2009, 4, e4505.	2.5	109
76	Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors. Journal of Virology, 2009, 83, 8925-8937.	3.4	170
77	Persistent Minority K103N Mutations among Women Exposed to Singleâ€Dose Nevirapine and Virologic Response to Nonnucleoside Reverseâ€Transcriptase Inhibitorâ€“Based Therapy. Clinical Infectious Diseases, 2009, 48, 462-472.	5.8	74
78	Viremia, Resuppression, and Time to Resistance in Human Immunodeficiency Virus (HIV) Subtype C during Firstâ€Line Antiretroviral Therapy in South Africa. Clinical Infectious Diseases, 2009, 49, 1928-1935.	5.8	107
79	Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance. Aids, 2009, 23, 809-816.	2.2	17
80	Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection. PLoS Pathogens, 2009, 5, e1000598.	4.7	213
81	Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma. Journal of Virology, 2009, 83, 1240-1259.	3.4	67
82	Cytotoxicological Analysis of a gp120 Binding Aptamer with Cross-Clade Human Immunodeficiency Virus Type 1 Entry Inhibition Properties: Comparison to Conventional Antiretrovirals. Antimicrobial Agents and Chemotherapy, 2009, 53, 3056-3064.	3.2	16
83	Broad Neutralization of Human Immunodeficiency Virus Type 1 Mediated by Plasma Antibodies against the gp41 Membrane Proximal External Region. Journal of Virology, 2009, 83, 11265-11274.	3.4	93
84	Human Immunodeficiency Virus-Specific Gamma Interferon Enzyme-Linked Immunospot Assay Responses Targeting Specific Regions of the Proteome during Primary Subtype C Infection Are Poor Predictors of the Course of Viremia and Set Point. Journal of Virology, 2009, 83, 470-478.	3.4	63
85	Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology, 2009, 385, 505-520.	2.4	78
86	High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology, 2009, 387, 414-426.	2.4	86
87	Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates. Virology, 2009, 393, 56-67.	2.4	14
88	Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nature Medicine, 2009, 15, 866-870.	30.7	390
89	Specificity of the autologous neutralizing antibody response. Current Opinion in HIV and AIDS, 2009, 4, 358-363.	3.8	59
90	Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. Journal of Virology, 2008, 82, 12449-12463.	3.4	548

#	Article	IF	Citations
91	Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C. Journal of Virology, 2008, 82, 11651-11668.	3.4	337
92	Active-Site Mutations in the South African Human Immunodeficiency Virus Type 1 Subtype C Protease Have a Significant Impact on Clinical Inhibitor Binding: Kinetic and Thermodynamic Study. Journal of Virology, 2008, 82, 11476-11479.	3.4	38
93	The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection. Journal of Virology, 2008, 82, 1860-1869.	3.4	142
94	4E10-Resistant Variants in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Individual with an Anti-Membrane-Proximal External Region-Neutralizing Antibody Response. Journal of Virology, 2008, 82, 2367-2375.	3.4	37
95	HIV Type 1 Subtype C Drug Resistance among Pediatric and Adult South African Patients Failing Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2008, 24, 1449-1454.	1.1	54
96	Development of Phenotypic HIV-1 Drug Resistance After Exposure to Single-Dose Nevirapine. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 538-543.	2.1	9
97	Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. Aids, 2008, 22, 1333-1343.	2.2	83
98	Establishing a Cohort at High Risk of HIV Infection in South Africa: Challenges and Experiences of the CAPRISA 002 Acute Infection Study. PLoS ONE, 2008, 3, e1954.	2.5	175
99	N-Linked Glycan Modifications in gp120 of Human Immunodeficiency Virus Type 1 Subtype C Render Partial Sensitivity to 2G12 Antibody Neutralization. Journal of Virology, 2007, 81, 10769-10776.	3.4	42
100	Polymorphisms in Nef Associated with Different Clinical Outcomes in HIV Type 1 Subtype C-Infected Children. AIDS Research and Human Retroviruses, 2007, 23, 204-215.	1.1	21
101	A Model of Directional Selection Applied to the Evolution of Drug Resistance in HIV-1. Molecular Biology and Evolution, 2007, 24, 1025-1031.	8.9	33
102	Longitudinal Analysis of HIV Type 1 Subtype C Envelope Sequences from South Africa. AIDS Research and Human Retroviruses, 2007, 23, 316-321.	1.1	25
103	Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination. Current Opinion in HIV and AIDS, 2007, 2, 169-176.	3.8	20
104	Selection and Persistence of Viral Resistance in HIV-Infected Children After Exposure to Single-Dose Nevirapine. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 148-153.	2.1	79
105	Transmission Rates in Consecutive Pregnancies Exposed to Single-Dose Nevirapine in Soweto, South Africa and Abidjan, CÃ´te d'Ivoire. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 206-209.	2.1	29
106	Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology, 2007, 368, 172-181.	2.4	45
107	HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. Aids, 2006, 20, 643-651.	2.2	78
108	Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. Aids, 2006, 20, 995-1002.	2.2	87

#	Article	IF	Citations
109	Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology, 2006, 356, 95-105.	2.4	59
110	High specificity of V3 serotyping among human immunodeficiency virus type-1 subtype C infected patients with varying disease status and viral phenotype. Journal of Medical Virology, 2006, 78, 1262-1268.	5.0	5
111	Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa. Journal of Virology, 2006, 80, 11776-11790.	3.4	334
112	Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent. Antimicrobial Agents and Chemotherapy, 2006, 50, 694-701.	3.2	78
113	Silencing of HIV-1 Subtype C Primary Isolates by Expressed Small Hairpin RNAs Targeted togag. AIDS Research and Human Retroviruses, 2006, 22, 401-410.	1.1	13
114	Resistance Mutational Analysis of HIV Type 1 Subtype C among Rural South African Drug-Naive Patients Prior to Large-Scale Availability of Antiretrovirals. AIDS Research and Human Retroviruses, 2006, 22, 1306-1312.	1.1	32
115	Nature of Nonfunctional Envelope Proteins on the Surface of Human Immunodeficiency Virus Type 1. Journal of Virology, 2006, 80, 2515-2528.	3.4	309
116	Genotypic and Phenotypic Characterization of Viral Isolates from HIV-1 Subtype C-Infected Children with Slow and Rapid Disease Progression. AIDS Research and Human Retroviruses, 2006, 22, 458-465.	1.1	51
117	A Reliable Phenotype Predictor for Human Immunodeficiency Virus Type 1 Subtype C Based on Envelope V3 Sequences. Journal of Virology, 2006, 80, 4698-4704.	3.4	124
118	Insensitivity of Paediatric HIV-1 Subtype C Viruses to Broadly Neutralising Monoclonal Antibodies Raised against Subtype B. PLoS Medicine, 2006, 3, e255.	8.4	72
119	Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors. Journal of Virological Methods, 2005, 125, 99-109.	2.1	10
120	Use of alternate coreceptors on primary cells by two HIV-1 isolates. Virology, 2005, 339, 136-144.	2.4	44
121	Emergence of Drugâ€Resistant HIVâ€1 after Intrapartum Administration of Singleâ€Dose Nevirapine Is Substantially Underestimated. Journal of Infectious Diseases, 2005, 192, 16-23.	4.0	214
122	Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration. PLoS Medicine, 2005, 2, e112.	8.4	262
123	Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines. Journal of Virology, 2005, 79, 10103-10107.	3.4	233
124	Characterization of Human Immunodeficiency Virus Type 1 from a Previously Unexplored Region of South Africa with a High HIV Prevalence. AIDS Research and Human Retroviruses, 2005, 21, 103-109.	1.1	24
125	In VitroGeneration of HIV Type 1 Subtype C Isolates Resistant to Enfuvirtide. AIDS Research and Human Retroviruses, 2005, 21, 776-783.	1.1	14
126	Use of a novel washing method combining multiple density gradients and trypsin for removing human immunodeficiency virus-1 and hepatitis C virus from semen. Fertility and Sterility, 2005, 84, 1001-1010.	1.0	50

#	Article	IF	Citations
127	Short Communication: Viral Dynamics and CD4+ T Cell Counts in Subtype C Human Immunodeficiency Virus Type 1-Infected Individuals from Southern Africa. AIDS Research and Human Retroviruses, 2005, 21, 285-291.	1.1	24
128	Incidence of HIVâ€1 Dual Infection and Its Association with Increased Viral Load Set Point in a Cohort of HIVâ€1 Subtype Câ€“Infected Female Sex Workers. Journal of Infectious Diseases, 2004, 190, 1355-1359.	4.0	119
129	Does Tuberculosis Increase HIV Load?. Journal of Infectious Diseases, 2004, 190, 1677-1684.	4.0	71
130	Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to G. Aids, 2004, 18, 2327-2330.	2.2	14
131	Characterization and Selection of HIV-1 Subtype C Isolates for Use in Vaccine Development. AIDS Research and Human Retroviruses, 2003, 19, 133-144.	1.1	113
132	Human Immunodeficiency Virusâ€“1 RNA Levels and CD4 Lymphocyte Counts, during Treatment for Active Tuberculosis, in South African Patients. Journal of Infectious Diseases, 2003, 187, 1967-1971.	4.0	68
133	Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine. Aids, 2003, 17, 1698-1700.	2.2	27
134	HIV-1 Subtype C Reverse Transcriptase Sequences from Drug-Naive Pregnant Women in South Africa. AIDS Research and Human Retroviruses, 2002, 18, 605-610.	1.1	38
135	HIV-1 Subtype A, D, G, AG and Unclassified Sequences Identified in South Africa. AIDS Research and Human Retroviruses, 2002, 18, 681-683.	1.1	30
136	Full-Length Genome Analysis of HIV-1 Subtype C Utilizing CXCR4 and Intersubtype Recombinants Isolated in South Africa. AIDS Research and Human Retroviruses, 2002, 18, 879-886.	1.1	39
137	Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa. Journal of Virology, 2002, 76, 2233-2244.	3.4	111
138	Neutralizing Antibody Responses to HIV-1 Infection. IUBMB Life, 2002, 53, 197-199.	3.4	9
139	Conserved Domains of Subtype C Nef from South African HIV Type 1-Infected Individuals Include Cytotoxic T Lymphocyte Epitope-Rich Regions. AIDS Research and Human Retroviruses, 2001, 17, 1681-1687.	1.1	20
140	Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140. Journal of Virology, 2001, 75, 579-588.	3.4	216
141	Characterization of Full-Length HIV Type 1 Subtype C Sequences from South Africa. AIDS Research and Human Retroviruses, 2001, 17, 1527-1531.	1.1	52
142	AIDS dissidents aren't victims â€” but the people their ideas kill will be. Nature, 2000, 405, 273-273.	27.8	0
143	Identification of HIV Type 1 Intersubtype Recombinants in South Africa Using env and gag Heteroduplex Mobility Assays. AIDS Research and Human Retroviruses, 2000, 16, 493-497.	1.1	20
144	Meningitis in a community with a high prevalence of tuberculosis and HIV infection. Journal of the Neurological Sciences, 1999, 162, 20-26.	0.6	41

#	Article	IF	Citations
145	The importance of doing HIV research in developing countries. Nature Medicine, 1998, 4, 1228-1229.	30.7	3
146	HIV-1 Antigenâ€“specific and â€“nonspecific B Cell Responses Are Sensitive to Combination Antiretroviral Therapy. Journal of Experimental Medicine, 1998, 188, 233-245.	8.5	234
147	Viral structure, replication, tropism, pathogenesis and natural history. , 0, , 87-96.		0
148	HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies. Journal of Virology, 0, , .	3.4	0